Advertisement

Topics

PubMed Journals Articles About "OpportunityAnalyzer Cystic Fibrosis Opportunity Analysis Forecasts 2025 Updated" RSS

19:56 EDT 23rd June 2018 | BioPortfolio

OpportunityAnalyzer Cystic Fibrosis Opportunity Analysis Forecasts 2025 Updated PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest OpportunityAnalyzer Cystic Fibrosis Opportunity Analysis Forecasts 2025 Updated articles that have been published worldwide.

More Information about "OpportunityAnalyzer Cystic Fibrosis Opportunity Analysis Forecasts 2025 Updated" on BioPortfolio

We have published hundreds of OpportunityAnalyzer Cystic Fibrosis Opportunity Analysis Forecasts 2025 Updated news stories on BioPortfolio along with dozens of OpportunityAnalyzer Cystic Fibrosis Opportunity Analysis Forecasts 2025 Updated Clinical Trials and PubMed Articles about OpportunityAnalyzer Cystic Fibrosis Opportunity Analysis Forecasts 2025 Updated for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of OpportunityAnalyzer Cystic Fibrosis Opportunity Analysis Forecasts 2025 Updated Companies in our database. You can also find out about relevant OpportunityAnalyzer Cystic Fibrosis Opportunity Analysis Forecasts 2025 Updated Drugs and Medications on this site too.

Showing "OpportunityAnalyzer Cystic Fibrosis Opportunity Analysis Forecasts 2025 Updated" PubMed Articles 1–25 of 31,000+

Lack of efficacy of Lactobacillus GG in reducing pulmonary exacerbations and hospital admissions in children with cystic fibrosis: A randomised placebo controlled trial.

Intestinal dysbiosis has been described in Cystic Fibrosis (CF) and probiotics have been proposed to restore microbial composition. Aim of the study was to investigate the effects of Lactobacillus rhamnosus GG (LGG) on clinical outcomes in children with cystic fibrosis (CF).


Audiometric assessment of pediatric patients with cystic fibrosis.

The purpose of this study was to evaluate hearing impairment in pediatric patients with cystic fibrosis (CF).

Normal sweat chloride test does not rule out cystic fibrosis.

Başaran AE, Karataş-Torun N, Maslak İC, Bingöl A, Alper ÖM. Normal sweat chloride test does not rule out cystic fibrosis. Turk J Pediatr 2017; 59: 68-70. A 5-month-old patient presented with complaints of fever and cough. He was hospitalized with the diagnosis of bronchopneumonia and pseudo-Bartter's syndrome. Patient was further investigated for diagnosis of cystic fibrosis. The chloride (Cl) level in sweat was determined within the normal range (25.1 mmol/L, 20.3 mmol/L). CFTR (Cystic Fibrosis Transm...


The association between Staphylococcus aureus and subsequent bronchiectasis in children with cystic fibrosis.

Staphylococcus aureus (S. aureus) may be related to more rapid progression of cystic fibrosis (CF) lung disease.

Fecal calprotectin concentrations in young children with cystic fibrosis: Authors response.

Faecal calprotectin concentrations in young children with cystic fibrosis.

No easy road to better cystic fibrosis care in Eastern Europe?

New Comorbidities in the Changing Face of Cystic Fibrosis Care.

Combined Pancreatic Islet-Lung-Liver Transplantation in a Pediatric Patient with Cystic Fibrosis-Related Diabetes.

Cystic fibrosis-related diabetes (CFRD) is the most frequent extrapulmonary complication of cystic fibrosis (CF).

Cost Effectiveness of Screening Individuals with Cystic Fibrosis for Colorectal Cancer.

Individuals with cystic fibrosis are at increased risk of colorectal cancer (CRC) compared to the general population, and risk is higher among those who received an organ transplant. We performed a cost-effectiveness analysis to determine optimal CRC screening strategies for patients with cystic fibrosis.

Cost-Effectiveness of Screening Individuals With Cystic Fibrosis for Colorectal Cancer.

Individuals with cystic fibrosis are at increased risk of colorectal cancer (CRC) compared to the general population, and risk is higher among those who received an organ transplant. We performed a cost-effectiveness analysis to determine optimal CRC screening strategies for patients with cystic fibrosis.

Cystic fibrosis transmembrane conductance regulator modulators: precision medicine in cystic fibrosis.

The aim of this study was to describe the newest development in cystic fibrosis (CF) care, CF transmembrane conductance regulator (CFTR) modulator therapies.

Chloride and sodium ion concentrations in saliva and sweat as a method to diagnose cystic fibrosis.

Cystic fibrosis diagnosis is dependent on the chloride ion concentration in the sweat test (≥60mEq/mL - recognized as the gold standard indicator for cystic fibrosis diagnosis). Moreover, the salivary glands express the CFTR protein in the same manner as sweat glands. Given this context, the objective was to verify the correlation of saliva chloride concentration (SaCl) and sweat chloride concentration (SwCl), and between saliva sodium concentration (SaNa) and sweat sodium concentration (SwNa), in patient...

Caregiver burden of parents of young children with cystic fibrosis.

There is a paucity of research examining the impact of informal caregiving on parents of young children with cystic fibrosis (CF). The aim of this study was to examine caregiver burden and identify risk factors associated with high caregiver burden in mothers and fathers of young children with CF.

First experience in Switzerland in Phe508del homozygous cystic fibrosis patients with end-stage pulmonary disease enrolled in a lumacaftor-ivacaftor therapy trial - preliminary results.

Cystic fibrosis is the most common genetic disorder in Caucasians. The combination of the cystic fibrosis transmembrane conductance regulator (CFTR) corrector lumacaftor / potentiator ivacaftor (LUM/IVA) has been shown to increase forced expiratory volume in 1 second (FEV1) moderately, but predominantly reduce acute exacerbation rate (AER) in Phe508del homozygous cystic fibrosis patients; however, patients with FEV1

Prognostic significance of pulmonary hypertension in patients with cystic fibrosis: A systematic review and meta-analysis.

Pulmonary hypertension (PH) is frequently found in advanced parenchymal lung diseases like cystic fibrosis (CF), but the role played by PH in the clinical outcome of CF patients remains unclear. The aim of this study is to determine the influence of PH on survival in the CF population by meta-analysis.

Long-term Microevolution of Pseudomonas aeruginosa Differs Between Mildly and Severely Affected Cystic Fibrosis Lungs.

The chronic airway infections with Pseudomonas aeruginosa determine morbidity in most individuals with cystic fibrosis (CF). P. aeruginosa may persist for decades in CF lungs which provides the rare opportunity to study the long-term within-host evolution of a bacterial airway pathogen.

Optimism, opportunities, outcomes: the Australian Cystic Fibrosis Data Registry.

The Australian Cystic Fibrosis Data Registry is positioning itself as an exemplar of a rare disease registry for the future. While it continues to inform cystic fibrosis (CF) clinicians of patterns of CF disease and quality of care, its capability is increasing as a resource for further research into CF subpopulations, as a platform for clinical trials, and as an interface for patient experiences.

Cystic Fibrosis Pulmonary Guidelines: Use of CFTR Modulator Therapy in Patients with Cystic Fibrosis.

CFTR modulators are a new class of medications that target the underlying defect in in cystic fibrosis (CF). Ivacaftor (IVA) and IVA combined with lumacaftor (IVA/LUM) have been approved by the FDA for use in CF patients. However, the FDA label for these medications encompasses patient groups that were not studied as part of the drug approval process. CF clinicians, patients, and their families have recognized a need for recommendations to guide the use of these medications.

ANTIBIOTIC RESISTANCE EVOLUTION OF PSEUDOMONAS AERUGINOSA IN CYSTIC FIBROSIS PATIENTS (2010-2013).

Pseudomonas aeruginosa is the predominant pathogen responsible of chronic colonization of the airways in Cystic Fibrosis patients. There are few European data about antibiotic susceptibility evolution of Pseudomonas aeruginosa in Cystic Fibrosis patients.

Examining the Stability of the Hospital Anxiety and Depression Scale Factor Structure in Adolescents and Young Adults With Cystic Fibrosis: A Confirmatory Factor Analysis.

The Hospital Anxiety and Depression Scale (HADS) is a widely used screening measure of anxiety and depression symptoms. However, prior analyses of the measure have found heterogeneous factor structures and called into question its ability to differentiate between symptoms of anxiety and depression. As part of efforts to implement mental health screening in cystic fibrosis (CF) care, the European Cystic Fibrosis Society (ECFS) and Cystic Fibrosis Foundation (CFF) conducted an international survey of 1,454 CF...

New directions on lung clearance index variability and feasibility.

Ion channels as targets to treat cystic fibrosis lung disease.

Lung health relies on effective mucociliary clearance and innate immune defence mechanisms. In cystic fibrosis (CF), an imbalance in ion transport due to an absence of chloride ion secretion, caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) and a concomitant sodium hyperabsorption, caused by dyregulation of the epithelial sodium channel (ENaC), results in mucus stasis which predisposes the lungs to cycles of chronic infection and inflammation leading to lung function dec...

Back to the source - Modern insights into pulmonary exacerbations and lung function decline from CF registry data.

Early detection using qPCR of Pseudomonas aeruginosa infection in children with cystic fibrosis undergoing eradication treatment.

Infection with Pseudomonas aeruginosa (Pa) with a chronic phenotype is associated with antibiotic eradication therapy (AET) failure. Our objective was to determine whether higher levels of Pa (detected using qPCR) prior to culture positivity were associated with AET failure in pediatric CF patients.


Advertisement
Quick Search
Advertisement
Advertisement